Publications by authors named "Annette Little"

Claim this Profile
T
The experience of point-of-care testing for influenza in Scotland in 2017/18 and 2018/19 - no gain without pain.
Elizabeth M Dickson, Diogo Fp Marques, Sandra Currie, Annette Little, Kirsty Mangin

Euro Surveill· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance.
Carlos le Sage, Steffen Lawo, Prince Panicker, Tim M E Scales, Syed Asad Rahman, Annette S Little

Sci Rep· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing the performance of pooled CRISPR-Cas9 drop-out screening.
Benedict C S Cross, Steffen Lawo, Caroline R Archer, Jessica R Hunt, Joanne L Yarker, Annette S Little

Sci Rep· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling.
Chia-Wen Hsu, Ruili Huang, Thai Khuc, David Shou, Joshua Bullock, Annette Little

Oncotarget· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
Annette S Little, Kathryn Balmanno, Matthew J Sale, Paul D Smith, Simon J Cook

Biochem Soc Trans· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
Annette S Little, Kathryn Balmanno, Matthew J Sale, Scott Newman, Jonathan R Dry

Sci Signal· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Annette S Little, Kathryn Balmanno, Matthew J Sale, Scott Newman, Jonathan R Dry

Sci Signal· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis